Hide metadata

dc.date.accessioned2018-03-21T09:55:25Z
dc.date.available2018-03-21T09:55:25Z
dc.date.created2017-04-04T09:31:45Z
dc.date.issued2017
dc.identifier.citationAbebe, Fekadu Belay, Mulugeta Legesse, Mengistu Mihret, Adane Franken, Kees L . Association of ESAT-6/CFP-10 induced IFN-gamma, TNF-alpha, IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts, and community controls in an endemic setting. Clinical and Experimental Immunology. 2017, 189(2), 241-249
dc.identifier.urihttp://hdl.handle.net/10852/61203
dc.description.abstractMycobacterium tuberculosis (Mtb) early secreted protein antigen 6 (ESAT‐6) and culture filtrate protein 10 (CFP‐10) are among candidate vaccines against tuberculosis (TB). Results of experimental animal models show that these antigens are associated with induction of strong T cell immunity [interferon (IFN)‐γ production], while others report that these proteins as virulent factors involved in pathogenicity of Mtb infection. However, the role of ESAT‐6/CFP‐10 during natural Mtb infections in humans has not been established. In this paper we present results of a longitudinal study from an Mtb‐infected human population from an endemic setting. Whole blood assay was used to determine levels of IFN‐γ, tumour necrosis factor (TNF)‐α and interleukin (IL)‐10 against rESAT‐6/CFP‐10 in TB patients, household contacts and community controls. The levels of IFN‐γ, TNF‐α and IL‐10 against rESAT‐6/CFP‐10 at baseline were significantly higher in patients and community controls than in household contacts. In patients, no significant difference was observed in the level of these cytokines before and after chemotherapy whereas, in contacts, the level of these cytokines increased significantly and progressively over time. The study shows that the levels of IFN‐γ, TNF‐α and IL‐10 against rESAT‐6/CFP‐10 are depressed during Mtb infection or exposure but are elevated during clinical TB. Our findings from a study of naturally infected human population suggest that IFN‐γ, TNF‐α and IL‐10 against rESAT‐6/CFP‐10 are markers for clinical TB but not for protective immunity.
dc.languageEN
dc.publisherBlackwell Science Ltd.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleAssociation of ESAT-6/CFP-10 induced IFN-gamma, TNF-alpha, IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts, and community controls in an endemic setting
dc.typeJournal article
dc.creator.authorAbebe, Fekadu
dc.creator.authorBelay, Mulugeta
dc.creator.authorLegesse, Mengistu
dc.creator.authorMihret, Adane
dc.creator.authorFranken, Kees L
cristin.unitcode185,52,14,0
cristin.unitnameAvdeling for samfunnsmedisin og global helse
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1
dc.identifier.cristin1463389
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical and Experimental Immunology&rft.volume=189&rft.spage=241&rft.date=2017
dc.identifier.jtitleClinical and Experimental Immunology
dc.identifier.volume189
dc.identifier.issue2
dc.identifier.startpage241
dc.identifier.endpage249
dc.identifier.doihttp://dx.doi.org/10.1111/cei.12972
dc.identifier.urnURN:NBN:no-63850
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0009-9104
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/61203/1/CEI-189-241.pdf
dc.type.versionPublishedVersion
dc.relation.projectNFR/196397/S50


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International